作者: Philip Gorwood
DOI: 10.1016/J.EURONEURO.2006.06.002
关键词: Antipsychotic 、 Anxiety 、 Psychiatry 、 Clinical psychology 、 Clinical trial 、 Schizophrenia 、 Tolerability 、 Substance abuse 、 Population 、 Psychology 、 Aripiprazole
摘要: Patients with schizophrenia and their physicians face a number of challenges, such as long-term control symptoms, maintaining cognitive function subjective well-being, preventing relapse. While randomised, placebo-controlled trials open-label extensions can provide valuable information about the efficacy tolerability newer antipsychotic agents, they cannot address all variables that may affect treatment outcome. Factors function, side effects, patients' attitudes to medication well being results in real-life clinical practice. Moreover, patient cohorts enrolled are often not reflective wider population schizophrenia. For example, patients conditions anxiety panic disorders or comorbid substance abuse, those severe illness from certain ethnic age groups, be excluded trials. In addition, themselves refuse participate studies because fear under-treated. Naturalistic are, therefore, an important means providing additional data on safety effectiveness agents 'real-world' settings. Studies Clinical Antipsychotic Trials Intervention Effectiveness (CATIE) study, Schizophrenia Outpatient Health Outcomes (SOHO) study Broad Trial Aripiprazole (BETA) studies, together large-scale database analyses, now producing supplementary observed long-term, extension studies. Such naturalistic will continue real-world atypical antipsychotics respect key outcomes continuation prolonged recovery.